AUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company...
Phase 2 clinical trial underway for Hypoplastic Left Heart Syndrome, which affects approximately 1,000 babies per yearMIAMI, Nov. 18, 2021...
Advaxis urges stockholders to vote “FOR” the merger with Biosight and all proposalsMONMOUTH JUNCTION, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE)...
NEWARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing...
Closing 100 Year-Old Missing Link: Dramatically Improves Pathology Workflow with Intelligent Robotics and Utilizes Proprietary Inputs for Next-Gen Precision Medicine...
VANCOUVER, British Columbia, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Simply Better Brands Corp. ("SBBC" or the "Company") (TSX Venture: SBBC)...
Biohaven to leverage Artizan’s biobanking expertise and proprietary drug discovery engine to create Parkinson’s disease drug development programNEW HAVEN, Conn.,...
NEW YORK and CLEVELAND, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene...
Anticipate Submission for Label Extension in First Half 2022YAVNE, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD)...
Company expects to initiate Phase 2 trial in basal cell carcinoma in 1Q 2022 Non-melanoma skin cancers are the most...
-Innovative financing facility and existing cash balance gives BridgeBio access to over $1.2 billion, which is expected to fully fund...
MENLO PARK, Calif. and BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering...
NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline...
IRVINE, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems AB (publ) (CLS), developer of high precision, image-guided focal...
100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy Preliminary findings show promising metabolic...
LUND, Sweden, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems AB (publ) (CLS), developer of high precision, image-guided focal...
BEDMINSTER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on...
TORONTO and HOUSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA),...
Peer Reviewed Results from PROPEL Show Treatment with AT-GAA Provided Clinically Meaningful Improvements Over Standard of Care, including ERT Experienced...
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"),...